



Evidence that the radioprotector effect of ascorbic acid depends on the radiation dose rate



Elena González^b, Martha P. Cruces^{a,*}, Emilio Pimentel^a, Petra Sánchez^b

^a Departamento de Biología, Instituto Nacional de Investigaciones Nucleares, Carretera México-Toluca S/N, La Marquesa, Ocoyoacac, 52750, Mexico

^b Universidad Autónoma del Estado de México Campus el Cerrillo Piedras Blancas, Carretera Toluca -Ixtilahuaca Km 15.5, Toluca de Lerdo, 50200, Mexico

ARTICLE INFO

Keywords:

Somatic mutation
D. melanogaster
Radiation dose rate
Ascorbic acid
Radioprotection
Wing test

ABSTRACT

Many studies have revealed that ascorbic acid (Aa) acts as a powerful inhibitor of genetic damage. The objective of the present study was to evaluate the radioprotector effect of Aa at two different radiation dose rates. The somatic mutation and recombination test in *Drosophila melanogaster* was used. 48 h larvae were treated for 24 h with 25, 50 and 100 mM of Aa. After pretreatment, larvae were irradiated with 20 Gy of gamma rays administered at 36 or 960 Gy/h. Toxicity, development rate and frequency of mutant spots were recorded. Results provide evidence of a radioprotective effect for all tested concentrations of Aa only when 20 Gy were delivered at 36 Gy/h and only with 25 mM using the 960 Gy/h. To consider the use of Aa as radioprotector or therapeutic agent, it is necessary to know its potential under different situations to avoid unwanted injuries.

1. Introduction

The harmful effects of ionizing radiation in biological systems are produced essentially through direct deposition of energy into crucial molecules (direct effect), or through the intracellular generation of reactive oxygen species (ROS) including superoxide anion, hydrogen peroxide, hydroxyl radicals, peroxide radicals, and other free radicals (Azzam et al., 2012). The most common reactive ROS include superoxide anion (O²⁻), hydrogen peroxide (H₂O₂) and hydroxyl radicals (OH). At low levels, ROS show beneficial effects: they participate in cellular response and immunity (Selim et al., 2016), but its excess provokes different effects including lipid peroxidation, removal of thiol groups from cellular and membrane proteins, strand breaks and base alterations leading to DNA damage (Shukla et al., 2010). Free radicals produce single and double DNA strand breaks, which lead to mutations. Nowadays, it is well known that DNA damage plays a significant role in the development of atherosclerosis and other degenerative diseases including some kind of autism, Alzheimer, Parkinson and cancer (Jones, 2010; Mironczuk-Chodakowska et al., 2018; Sanz, 2016). The risk of injury from radiation is a function of the doses received; the type of radiation (low or high linear energy transfer), the type of cell and dose rate, among others (Kelsey et al., 2014). Dose rate is defined as the radiation dose absorbed per unit of time (Ślosarek et al., 2014).

Nowadays, the extensive use of radiation for medical treatment, diagnosis; its use in the energy sector, industry, nuclear accidents,

nuclear terrorism and in some other activities such as outer space or air traveling, has increased the necessity to identify, develop, and validate potential strategies to protect normal tissues from the harmful effects of ionizing radiation (Singh and Krishnan, 2015). Pharmacological intervention could be the most prudent strategy, given that compounds, especially those of natural origin that can act as free radical scavengers and antioxidants, are able to reduce or mitigate the deleterious effects of ionizing radiation (Maurya et al., 2006).

Radioprotective agents are chemical compounds that reduce the effects of radiation in healthy tissues and have been used to reduce morbidity or mortality produced by ionizing radiation (Greenberger, 2009), they also have a practical use in clinical radiotherapy because normal tissues should be protected against radiation injury while cancerous tissues are exposed to higher doses of radiation to obtain better results. A large number of compounds showed good radioprotection in *in vitro* studies, but most of them failed *in vivo* application due to acute toxicity and side effects (Weiss and Landauer, 2003). There have been many attempts to find an ideal radioprotector that can preferentially protect normal tissues from radiation damage without affecting the sensitivity of tumor cells (Bump and Malaker, 1997). The chemicals that can scavenge free radicals reduce the occurrence of DNA strand breaks. Thus they can prevent the formation of free radicals or destroy free radicals by reacting with them, thereby inhibiting their reaction with biomolecules. Since free radicals are short-lived, it is necessary for such radioprotective molecules to be present in the cellular media at the

* Corresponding author.

E-mail address: marthapatricia.cruces@inin.gob.mx (M.P. Cruces).

<https://doi.org/10.1016/j.etap.2018.07.015>

Received 7 March 2018; Received in revised form 30 July 2018; Accepted 31 July 2018

Available online 01 August 2018

1382-6689/ © 2018 Elsevier B.V. All rights reserved.

time of radiation exposure.

To keep the damage caused by ROS from occurring, eukaryotic cells possess antioxidant systems, such as enzymes that prevent or limit the free radical production: superoxide dismutase, catalase, and glutathione peroxidase. These enzymes provide important protection against radiation exposure (Pisochi and Pop, 2015). Besides the enzymes, the cell can prevent the free radical damage by means of dietary antioxidants, including vitamins A, C, and E, polyphenols, anthocyanins, flavonoids and isothiocyanates (Weiss and Landauer, 2003; Meyers et al., 2008).

Vitamin C is the reduced form of ascorbic acid (Aa), it is a water-soluble ketolactone with two ionizable hydroxyl groups that readily undergoes two consecutive one-electron oxidations to form the poorly reactive ascorbate radical and the dehydroascorbic acid (Du et al., 2012). Administration of Aa before gamma irradiation prevents chromosomal damage in bone marrow cells and radiation-induced lethality (Konopacka et al., 1998). The protective properties of this compound are due mainly to its scavenging activity of reactive oxygen species before they reach macromolecules, protecting lipid membranes and proteins from oxidative damage (Berger et al., 1997). It has been reported that Aa can prevent the adverse effects of whole body irradiation through increasing the antioxidant defense systems in the liver and kidney of irradiated animals (Mortazavi et al., 2015). Pretreatment with Aa inhibits lipid peroxidation, protects mice against mortality and sickness induced by irradiation, and produces an improvement of wound healing after exposure to whole body gamma radiation (Prasad et al., 2002).

Different factors modify the effect of Aa, the most studied are the concentration and the presence of transition metals (Halliwell, 1999), several experiments have shown that high concentrations of Aa increased DNA damage through the production of hydroxyl radicals from hydrogen peroxide by the Fenton reaction. Du et al. (2012) found that pharmacological doses of ascorbate induce cytotoxicity and oxidative stress in pancreatic cancer cells, but not in normal cells. Several studies have revealed that Aa, can also have prooxidant effects (Halliwell, 1996); in fact, the combination of transition metals (such as Fe and Cu) with ascorbate has long been used as an oxidizing system, and the combination of these two reagents also known as the “unfriend system” is used for the hydroxylation of alkanes, aromatics, and other oxidations (Odin, 1997; Halliwell, 1999; Cai et al., 2001; Mendes-da-Silva et al., 2014).

Although different experiments have been conducted to determine the radioprotective effect of ascorbic acid, results are not consistent so it is essential to explore under what circumstances antioxidants can decrease or increase the genetic damage caused by ionizing radiation. One of the factors modifying the effect of ionizing radiation is the dose rate which is very important in radiotherapy, that is why the main objective of the present work is to evaluate the radio protective effect of Aa using two different dose rates by means of the somatic mutation and recombination test (SMART) in the wing blade of *Drosophila*.

Since *Drosophila* is a holometabolous organism, toxicity can be assessed in the different developmental stages: embryo, larval, pupal, and adult. Various parameters such as: toxicity, development rate and genetic damage could be tested using the same individuals, under which circumstances antioxidants can protect from damage induced by ionizing radiation or increases it. From a radiobiological point of view, it is known that mitotic recombination is inducible by radiation and its significance in human oncogenesis is remarkable, the *Drosophila* SMART test offers the great advantage of strongly identifying this genetic point. Therefore, *D. melanogaster* could bring an essential contribution to the antimutagenic and radio protection field.

2. Material and methods

Biological material and pretreatment: Three-day-old virgin *mwh/mwh* females were mated to *flr³/TM3 Ser* males in 250 ml flasks with

regular food. Oviposition was restricted to 2 h to obtain homogeneous samples. Eggs were incubated in the culture room for 72 h to obtain second instar larvae that were separated from the culture medium by means of gradient density using a 20% sucrose solution. Larvae were treated for 24 h in empty bottles containing a disc of filter paper and 3.5 ml of 0, 25, 50 and 100 mM of Aa solution, using distilled water as solvent. Aa concentrations, treatment period as well as genetic damage-inducing dose were selected based on previous work in our laboratory (Olvera et al., 1995, 1997; Cruces et al., 2003, 2009).

Treatment with radiation: After Aa pretreatment, larvae for each concentration were divided in three groups: the first was irradiated with 20 Gy at low DR (LDR): 36 Gy/h in the Gamma-Cell 2000 irradiator, the second at high DR (HDR): 960 Gy/h in the Transelektro LGI-01 irradiator, and the third group was used as control. 1000 larvae were tested for each treatment in groups of 100 by homeopathic vial with 0.8 g of synthetic medium (Formula 4–24 Carolina Biological Supply Co.) and 2.5 ml of distilled water. All treated larvae were introduced into the culture room. After larvae completed their development, the number of emerged adults, males and females separately, were recorded daily.

Developmental rate and larvae-to-adult viability analysis: Larvae-to-adult developmental rate was determined by counting every day the number of emerged flies, until all had emerged, larvae-to-adult survival was measured as the ratio of the total number of emerged flies and toxicity was obtained by dividing total viable adults into the number of treated larvae. Once that data was obtained, survival curves were constructed. The slope (m) of the exponential phase of each curve was calculated for the development rate index and the emergence day for 50% of the individuals was determined by extrapolating the X axis. The Chi square test was used to establish differences between treatments.

Genotoxicity analysis: The wings of the subsequently emerged adults were mounted on slides following the standard procedure described by Graf et al. (1984). The wings were scored at 40x magnification for abnormal wing hair spots in small singles (1 or 2 cells), large (more than 3 cells) either *mwh* or *flr* and twin spots. Single *mwh* spots are inferred to arise from a separation between *mwh* and *flr³*, from an interchange or from mutation/deletion at the *mwh⁺* locus; single *flr* spots occur from mutation/deletion at the *flr⁺* locus or following a double exchange; and twin spots from an interchange between *flr* and the centromere. The frequencies of each type of mutant clones per wing (s/p) were compared with the concurrent negative control.

Statistical analysis: The Chi-square test was used to identify statistical differences in larvae-to-adult survival between control and the remaining groups and to determine differences between genetic damage caused by different treatments.

3. Results

Developmental rate and larvae-viability analysis: Table 1 shows viability of second instar larvae treated with Aa 25, 50 or 100 mM, none of them decreased viability, however, in combination with 20 Gy at a HDR 50 and 100 mM they reduced the viability although no significant differences were found. Fig. 1 represents the development rate of the organisms treated with different concentrations of Aa and its treatment combined with 20 Gy gamma rays administered at two different dose rates. No differences were found between the slopes of the different treatments and the control groups.

Genotoxicity analysis: Table 2 shows the frequency of all kinds of spots (small, large, twin and total) produced by the treatment with the three Aa concentrations and in combination with 20 Gy of gamma rays administered at low or high dose ratios. None of the Aa concentrations modified the basal frequency of mutations, 20 Gy of gamma rays administered at 36 Gy/h, provoked an increase of 11.7 times in the total spots over the basal frequency. The lowest concentration of Aa combined with gamma rays reduced the frequencies of spots induced by 20 Gy: the small in 40%; the large in 20% and the total in 23%. The

Table 1

Viability percentage of second instar larvae treated with Aa and 20 Gy of gamma rays at two different DR.

| Treatment Aa (mM) | No. of larvae | No. Adults. \pm SEM | Viability % |
|---------------------------|---------------|-----------------------|-------------|
| 0 | 1000 | 907 \pm 2.4 | 90.7 |
| 25 | 1000 | 880 \pm 3.2 | 88.0 |
| 50 | 1000 | 838 \pm 1.6 | 83.8 |
| 100 | 1000 | 826 \pm 5.2 | 82.6 |
| Low Dose Rate (36 Gy/h) | | | |
| 20 Gy | 1000 | 888 \pm 2.1 | 88.8 |
| 25 + | 1000 | 841 \pm 1.8 | 84.1 |
| 50 + | 1000 | 834 \pm 1.8 | 83.4 |
| 100 + | 1000 | 816 \pm 3.3 | 81.6 |
| High Dose Rate (960 Gy/h) | | | |
| 20 Gy | 1000 | 858 \pm 3.6 | 85.8 |
| 25 + | 1000 | 815 \pm 1.1 | 81.5 |
| 50 + | 1000 | 784 \pm 1.0 | 78.4 |
| 100 + | 1000 | 799 \pm 1.7 | 79.9 |

The table presents three sections: the first one refers to the larvae-viability induced by the Aa at the three tested concentrations; the second section refers to the effect of Aa against a low DR and the third section against a high DR. +: refers to treatment, plus 20 Gy at the corresponding DR.




Fig. 1. Development rate (m) of the organism treated with Aa and 20 Gy of gamma rays at two different DR.

combined treatment of 50 mM Aa + 20 Gy reduced 68% the small, 32% the large, 63% the twin and 49% the total spots, and the combined treatment 100 mM Aa + 20 Gy reduced 35% the small, 31% the large, 20% the twin and 29% the total spots.

The HDR (960 Gy/h) increased 19 times the basal frequency of mutations (from 0.31 to 5.93) and provoked a significant diminution in genetic damage in combination with 25 mM of Aa in all kind of spots ($p \leq 0.001$, 0.02 and 0.05 for small, single and twin spots respectively). No concentration relationship with Aa was found neither with the low nor with the HDR.

4. Discussion

Although radioprotection studies started 50 years ago, and several compound have been screened for their radio protective capacity, the practical applicability of the majority of these synthetic compounds has remained limited, due to their toxicity at their optimum protective dose (Prasad et al., 2002) and nowadays the use of natural compounds seems to be the most favorable choice.

Dietary antioxidants are widely used as dietary supplements; many

studies suggested that these might promote health (Rahal et al., 2014). Aa has been reported to be an effective antioxidant and free radical scavenger in *in vivo* and *in vitro* conditions, it reduces oxidative and free radical-induced damage to DNA and membranes in biological systems (Halliwell, 2006). It has been demonstrated that treatment with Aa has also significantly reduced the genotoxicity of well-known mutagens (Odin, 1997) and it is considered to be a dietary radioprotective agent due to its action as a reactive oxygen scavenger (Du et al., 2012). Most studies have shown that vitamin C either reduces oxidative DNA damage or has a null effect, whereas some reviews have shown an increase in specific base lesions (Putchala et al., 2013).

In the present study it was found that the 24h-pretreatment with Aa, did not cause changes in the development rate (m) with any of the Aa concentrations or in combination with the two DR (Fig. 1). A non-statistical significant decrease in larva-to-adult viability was observed with 50 and 100 mM of Aa in combination with the HDR, and a minimum delay in development rate was observed when controls were compared against the two DR. Based on the fact that DR is one of the physical factors that modify the cellular response to radiation (Brooks et al., 2016), the results of the present study showed that the DR has important implications for genetics and radioprotection. In radiobiology it is assumed that doses administered at a LDR produce a less significant biological effect because the cell can repair the damage. Narra et al. (1993) found a greater radioprotective effect of Aa in mice spermatozoa when Iodine-¹³¹ was incorporated than when radiation was administered in acute form. A possible explanation for our results is that at a HDR, greater the amount of free radicals and Aa is unable to inactivate even at higher concentrations. Electromagnetic ionizing radiation induces damage primarily through free radicals (Hiscock, 1999). The radioprotective effect of Aa has been ascribed to its interactions with radiation-induced free radicals (Mathew et al., 2007). Then the basis for this research is that, Aa can stabilize the free radicals donating one of their electrons and in this way prevent them from causing damage to the molecules. No antioxidant has an effect on the direct effect of ionizing radiation.

Fujii et al. (2010) reported that in normal human fibroblast cells, Aa treatment enhanced cell survival after been irradiated with X-rays, but not after heavy ions irradiation. They concluded that Aa treatment is not powerful enough to protect complex type of DNA damage induced by heavy ions. Although the same type of radiation was used in this report, some authors have suggested that HDR caused damage by means of direct effect, which cannot be avoided by the action of antioxidants and DNA double strand breaks (DSBs) are the most important type of damage provoked.

The results of this study provide evidence of the protective capacity of Aa against radiation damage induced at LDR probably as a synergistic effect with endogenous antioxidants capable of acting and / or being induced to these levels of DR. Yang et al. (2017) found that the administration of vitamin C increased the activity of oxidative enzymes SOD and CAT which reduced ROS concentration on cells on *Pichia caribbica*. Using *Drosophila* it was reported that DJ-1 β mutant flies treated with α -tocopherol or vitamin C exhibited a significant increase in catalase activity compared with untreated individuals which was accompanied with a decrease in ROS levels (Casani et al., 2013).

Our results show that only when 20 Gy was administered at a HDR larvae-adult viability diminished, (although no statistical significant differences were found), we can suggest that the absence of protection of Aa in combination with the HDR was probably a consequence of Aa toxicity (13.5% and 11.8% with 50 and 100 mM respectively) added with a higher amount of free radicals induced by the HDR in comparison with those produced by the same dose of gamma rays but at a LDR. So DR plays a central role in the effect of Aa. So for the authors the effect might be due to the DR.

Therefore, further experiments are required to determine the conditions under which Aa can protect healthy cells. The results obtained in the present study enhance the necessity to test the different situations

Table 2Mutation frequency induced in 48 h *mw* +/+ *flr*³ *D. melanogaster* larvae retreated with 20 Gy of gamma rays at two different DR.

| Aa (mM) | # W | Spots | | | | | | | | P values | | | |
|--------------------|-----|---------------|------|---------------|------|------|------|-------|------|-----------|-----------|-----------|-----------|
| | | Small Singles | | Large Singles | | Twin | | Total | | SS | LS | TW | T |
| | | # | s/w | # | s/w | # | s/w | # | s/w | | | | |
| 0 | 80 | 16 | 0.20 | 7 | 0.09 | 2 | 0.03 | 25 | 0.31 | | | | |
| 25 | 80 | 19 | 0.24 | 0 | 0 | 0 | 0 | 19 | 0.24 | 0.65 | < 0.01 | 0.2 | 0.4 |
| 50 | 80 | 24 | 0.30 | 4 | 0.05 | 1 | 0.01 | 29 | 0.36 | 0.20 | 0.4 | 0.6 | 0.6 |
| 100 | 80 | 19 | 0.24 | 4 | 0.05 | 3 | 0.04 | 23 | 0.29 | 0.65 | 0.4 | 0.7 | 0.8 |
| Dose rate 36 Gy/h | | | | | | | | | | | | | |
| 20Gy | 160 | 193 | 1.21 | 302 | 1.89 | 86 | 0.54 | 581 | 3.63 | | | | |
| 25 + | 160 | 116 | 0.73 | 242 | 1.52 | 86 | 0.54 | 444 | 2.78 | ↓ < 0.001 | ↓ < 0.025 | 0.999 | ↓ < 0.001 |
| 50 + | 160 | 62 | 0.39 | 204 | 1.28 | 31 | 0.20 | 297 | 1.86 | ↓ < 0.001 | ↓ < 0.001 | ↓ < 0.001 | ↓ < 0.001 |
| 100 + | 160 | 126 | 0.79 | 209 | 1.31 | 68 | 0.43 | 403 | 2.52 | ↓ < 0.001 | ↓ < 0.001 | 0.15 | ↓ < 0.001 |
| Dose rate 960 Gy/h | | | | | | | | | | | | | |
| 20Gy | 160 | 158 | 0.99 | 593 | 3.71 | 198 | 1.24 | 949 | 5.93 | | | | |
| 25 + | 160 | 89 | 0.56 | 509 | 3.18 | 156 | 0.98 | 754 | 4.71 | ↓ < 0.001 | ↓ < 0.025 | ↓ < 0.05 | ↓ < 0.001 |
| 50 + | 160 | 142 | 0.89 | 667 | 4.17 | 201 | 1.26 | 1010 | 6.31 | 0.4 | ↑ < 0.05 | 0.9 | 0.2 |
| 100 + | 160 | 153 | 0.96 | 565 | 3.53 | 193 | 1.21 | 911 | 5.69 | 0.8 | 0.45 | 0.85 | 0.4 |

The table expresses the mean of three independent experiments. The symbols ‘#’ and ‘s/w’ stands for the number of spots and the frequency of spots per wing, respectively. The four columns headed by P values refer to the probability of the difference in ‘s/w’ values between each of the experimental concentrations vs. control. Arrows pointing down ↓ represent significant decrease, those pointing up ↑ a significant increase, compared with the control.

in which Aa can be used: external or internal exposure, acute high-dose radiation in contrast to chronic exposure, etc. To avoid an increase in genetic damage provoked by radiation, it has been suggested the use of antioxidants to protect healthy cells of patients receiving radiotherapy as a treatment for cancer.

Disclosure statement

The authors confirm the absence of any conflict of interest. The authors are responsible for the content and writing of the paper.

Transparency document

The Transparency document associated with this article can be found in the online version.

Acknowledgements

The work was supported by a grant (No. 167461) to M. P. Cruces from the Consejo Nacional de Ciencia y Tecnología (CONACyT), Mexico, and it involved some research by María Elena González Herrera to obtain the Ph D at the Universidad Autónoma del Estado de México (UAEM) with a fellowship (586704) from CONACyT. The authors wish to acknowledge the technical assistance provided by Hugo Suárez Contreras.

References

- Azzam, E.I., Jay-Gerin, J.P., Pain, D., 2012. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. *Cancer Lett.* 327 (1), 48–60.
- Berger, T.M., Polidori, M.C., Dabbagh, A., Evans, P.J., Halliwell, B., Morrow, J.D., Frei, B., 1997. Antioxidant activity of vitamin C in iron-overloaded human plasma. *J. Biol. Chem.* 272 (25), 15656–15660.
- Brooks, A.L., Hoel, D.G., Preston, R.J., 2016. The role of dose rate in radiation cancer risk: evaluating the effect of dose rate at the molecular, cellular and tissue levels using key events in critical pathways following exposure to low LET radiation. *Int. J. Rad. Biol.* 92 (8), 405–426.
- Bump, E.A., Malaker, K., 1997. Radioprotectors: Chemical, Biological, and Clinical Perspectives. CRC press.
- Cai, L., Koropatnick, J., Cherian, M.G., 2001. Roles of vitamin C in radiation-induced DNA damage in presence and absence of copper. *Chem. Biol. Interact.* 137 (1), 75–88.
- Casani, S., Gómez-Pastor, R., Matallana, E., Paricio, N., 2013. Antioxidant compound supplementation prevents oxidative damage in a *Drosophila* model of Parkinson's disease. *Free Radic. Biol. Med.* 61, 151–160.
- Cruces, M.P., Pimentel, E., Zimmering, S., 2003. Evidence suggesting that chlorophyllin (CHLN) may act as an inhibitor or a promoter of genetic damage induced by chromium (VI) oxide (CrO₃) in somatic cells of *Drosophila*. *Mutat. Res./Genet. Toxicol. Environ. Mutagen.* 536 (1), 139–144.
- Cruces, M.P., Pimentel, E., Zimmering, S., 2009. Evidence that low concentrations of chlorophyllin (CHLN) increase the genetic damage induced by gamma rays in somatic cells of *Drosophila*. *Mutat. Res.* 679 (1), 84–86.
- Du, J., Cullen, J.J., Buettner, G.R., 2012. Ascorbic acid: chemistry, biology and the treatment of cancer. *Biochim Biophys Acta (BBA)-Reviews on Cancer* 1826 (2), 443–457.
- Fujii, Y., Kato, T.A., Ueno, A., Kubota, N., Fujimori, A., Okayasu, R., 2010. Ascorbic acid gives different protective effects in human cells exposed to X-rays and heavy ions. *Mutat. Res./Genet. Toxicol. Environ. Mutagen.* 699 (1), 58–61.
- Graf, U., Würigler, F.E., Katz, A.J., Frei, H., Juon, H., Hall, C.B., Kale, P.G., 1984. Somatic mutation and recombination test in *Drosophila melanogaster*. *Environ. Mutagen.* 6, 153–188.
- Greenberger, J.S., 2009. Radioprotection. *In Vivo* 23, 323–336.
- Halliwell, B., 1996. Commentary: vitamin C: antioxidant or pro-oxidant in vivo? *Free. Rad. Res* 25, 439–454.
- Halliwell, B., 1999. Vitamin C: poison, prophylactic or panacea? *Trends Biochem. Sci.* 24, 255–259.
- Halliwell, B., 2006. Oxidative stress and neurodegeneration: where are we now? *J. Neurochem.* 97, 1634–1658.
- Hiscock, R.R., 1999. Radiation protection in medical radiography. *Radiol. Technol.* 70 (6), 592.
- Jones, J.A., 2010. 14.10-ionizing radiation as a carcinogen A2-McQueen, Charlene A. *Comprehensive Toxicology*.
- Kelsey, C.A., Heintz, P.H., Chambers, G.D., Sandoval, D.J., Adolph, N.L., Paffett, K.S., 2014. *Radiation Biology Of Medical Imaging*. John Wiley & Sons.
- Konopacka, M., Widel, M., Rzeszowska-Wolny, J., 1998. Modifying effect of vitamins C, E and beta-carotene against gamma-ray-induced DNA damage in mouse cells. *Mutat. Res.* 417 (2), 85–94.
- Mathew, D., Nair, C.K.K., Jacob, J.A., Biswas, N., Mukherjee, T., Kapoor, S., Kagiya, T.V., 2007. Ascorbic acid monoglucoside as antioxidant and radioprotector. *J. Radiat. Res.* 48 (5), 369–376.
- Maurya, D.K., Devasagayam, T., Nair, C.K.K., 2006. Some novel approaches for radioprotection and the beneficial effect of natural products. *Indian J. Exp. Biol.* 44, 93–114.
- Mendes-da-Silva, R.F., Lopes-de-Morais, A.A.C., Bandim-da-Silva, M.E., de Araujo Cavalcanti, G., Rodrigues, A.R.O., da Silveira Andrade-da, B.L., Guedes, R.C.A., 2014. Prooxidant versus antioxidant brain action of ascorbic acid in well-nourished and malnourished rats as a function of dose: a cortical spreading depression and malondialdehyde analysis. *Neuropharmacology* 86, 155–160.
- Meyers, K.J., Rudolf, J.L., Mitchell, A.E., 2008. Influence of dietary quercetin on glutathione redox status in mice. *J. Agric. Food Chem.* 56 (3), 830–836.
- Mirończuk-Chodakowska, I., Witkowska, A.M., Zujko, M.E., 2018. Endogenous non-enzymatic antioxidants in the human body. *Adv. Med. Sci.* 63 (1), 68–78.
- Mortazavi, S.M.J., Foadi, M., Mozdarani, H., Haghani, M., Mosleh, S.M., Abolghasemi, P., Sharifzadeh, S., 2015. Future role of vitamin C in radiation mitigation and its possible applications in manned deep space missions: survival study and the measurement of cell viability. *IJRR* 13, 55–60.
- Narra, V.R., Howell, R.W., Sastry, K.S., Rao, D.V., 1993. Vitamin C as a radioprotector against iodine-131 in vivo. *J. Nucl. Med.* 34, 637–640.

- Odin, P., 1997. Vitamins as antimutagens: advantages and some possible mechanisms of antimutagenic action. *Mutat. Res.* 386, 39–67.
- Olvera, O., Zimmering, S., Arceo, C., Guzman, J., De la Rosa, M.E., 1995. Evidence for the protective effect of ascorbic acid (vitamin C) in treatment with γ -rays and chromium (VI) oxide (CrO_3) in somatic cells of *Drosophila*. *Mutat. Res. Lett.* 346 (1), 19–21.
- Olvera, O., Zimmering, S., Cruces, M.P., Pimentel, E., Arceo, C., Guzmán, J., De la Rosa, M.E., 1997. Antimutagenesis in somatic cells of *Drosophila* as monitored in the wing spot test. *Food Factors for Cancer Prevention*. Springer, Tokyo pp. 567–571.
- Pisoschi, T., Pop, A.M., 2015. The role of antioxidants in the chemistry of oxidative stress: a review. *Eur. J. Med. Chem.* 5 (June (97)), 55–74 2015.
- Prasad, K., Cole, W.C., Kumar, B., Prasad, K.C., 2002. Pros and cons of antioxidant use during radiation therapy. *Cancer Treat. Rev.* 28, 79–91.
- Putchala, M.C., Ramani, P., Sherlin, H.J., Premkumar, P., 2013. Ascorbic acid and its prooxidant activity as a therapy for tumours of oral cavity—a systematic review. *Arch. Oral Biol.* 2013 (58), 563–574.
- Rahal, A., Kumar, A., Singh, V., Yadav, B., Tiwari, R., Chakraborty, S., Dhama, K., 2014. Oxidative stress, prooxidants, and antioxidants: the interplay. *Biomed Res. Int.* 1–19.
- Sanz, A., 2016. Mitochondrial reactive oxygen species: do they extend or shorten animal lifespan? *Biochim. Biophys. Acta* 1857, 1116–1126.
- Selim, M., Saha, A., Mukherjee, K.K., 2016. Protection of radiation induced DNA damage by a newly developed molybdenum complex. *J. Radioanal. Nucl. Chem.* 31, 189–193.
- Shukla, P.C., Singh, K.K., Yanagawa, B., Teoh, H., Verma, S., 2010. DNA damage repair and cardiovascular diseases. *Can. J. Cardiol.* 26, 13–16.
- Singh, P.K., Krishnan, S., 2015. Vitamin E analogs as radiation response modifiers. *Evid. Complement. Alternat. Med.* 2015, 1–16.
- Ślosarek, K., Konopacka, M., Rogoliński, J., Sochanik, A., 2014. Effect of dose-rate and irradiation geometry on the biological response of normal cells and cancer cells under radiotherapeutic conditions. *Mutat. Res.* 773, 14–22.
- Weiss, J.F., Landauer, M.R., 2003. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. *Toxicology* 189, 1–20.
- Yang, Q., Li, Y., Li, C., Zhang, H., Jiang, Z., Zhang, X., Zhu, S., 2017. Antioxidative enzymes and substances involve in the activity of improving the oxidative tolerance of *Pichia caribbica* by ascorbic acid. *Biol. Control* 108, 83–88.